Anika Therapeutics, Inc.
Net Cash Flow Breakdown
FY2025
FY2024
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
FY2010
FY2009
Total Cash from Operations: $42.6M
| Line Item | Value | % of Total |
|---|---|---|
| Capital Expenditures | $9.0M | 21.1% |
| Other Investing | $3.5M | 8.2% |
| Working Capital | $1.1M | 2.6% |
| Net Cash Flow | $29.0M | 68.1% |